Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Sets New 12-Month High – What’s Next?

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF)’s share price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $52.25 and last traded at $52.25, with a volume of 0 shares trading hands. The stock had previously closed at $52.25.

Analyst Ratings Changes

Separately, Royal Bank of Canada upgraded shares of Recordati Industria Chimica e Farmaceutica to a “hold” rating in a research report on Monday.

Recordati Industria Chimica e Farmaceutica Stock Performance

The stock has a market capitalization of $10.78 billion, a P/E ratio of 18.80 and a beta of 0.33. The company has a current ratio of 1.36, a quick ratio of 0.95 and a debt-to-equity ratio of 0.73. The business has a 50-day moving average price of $52.22 and a two-hundred day moving average price of $51.82.

Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) last announced its quarterly earnings data on Tuesday, July 30th. The company reported $0.70 earnings per share (EPS) for the quarter. The business had revenue of $622.00 million for the quarter. Recordati Industria Chimica e Farmaceutica had a net margin of 17.41% and a return on equity of 30.78%.

Recordati Industria Chimica e Farmaceutica Company Profile

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.